![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1040-8401&client=dukeuniv)
Quantitating therapeutically relevant T-cell responses to cancer vaccines.
Successful application of active immunotherapy to the treatment of cancer will require stimulation of potent antigen-specific T-cell responses. It is not known how numerous or how potent these T cells must be in order to abrogate tumors, but the levels of immunity needed to control chronic viral infections may provide estimates for comparison. Evaluation of the efficacy of a vaccine strategy in attaining these levels of immunity will depend on the use of assays that create a picture of T-cell number and function that correlates with clinical outcomes. We discuss the currently available in vivo and in vitro T-cell assays and their relevance for detecting therapeutic levels of T-cell activity. We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials.
Duke Scholars
Published In
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- T-Lymphocytes
- RNA, Messenger
- Lymphocyte Activation
- Immunology
- Hypersensitivity, Delayed
- Humans
- Flow Cytometry
- Enzyme-Linked Immunosorbent Assay
- Cytotoxicity Tests, Immunologic
- Cytokines
Citation
![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1040-8401&client=dukeuniv)
Published In
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- T-Lymphocytes
- RNA, Messenger
- Lymphocyte Activation
- Immunology
- Hypersensitivity, Delayed
- Humans
- Flow Cytometry
- Enzyme-Linked Immunosorbent Assay
- Cytotoxicity Tests, Immunologic
- Cytokines